Boston Scientific to Acquire Penumbra in $14.5 Billion Deal to Expand Cardiovascular Portfolio

　　【Pharmaceutical Network - Corporate News] Recently, Boston Scientific announced that it will acquire medical technology company Penumbra in a cash-and-stock transaction, with an enterprise value of approximately $14.5 billion. The acquisition aims to expand Boston Scientific’s cardiovascular product portfolio, and the transaction is expected to be completed in 2026.
 

Public information indicates that Penumbra is a U.S. medical technology company focused on the design, development, manufacture, and sale of innovative medical devices. The company boasts an extensive product portfolio addressing challenging medical conditions and significant clinical needs across two major markets: neurovascular and peripheral vascular. Upon completion of the transaction, Boston Scientific’s market position in the medical device sector will be further consolidated, while also creating new opportunities for Penumbra’s future growth.
 

It is worth noting that the acquisition of Penumbra is merely a microcosm of Boston Scientific’s expansion strategy. Reportedly, in recent years, the company has centered its approach on “securing positions in high-barrier sectors, complementing technology platforms, and leveraging commercial synergies,” while frequently launching acquisitions focused on high-growth areas such as cardiovascular intervention, neuromodulation, and urology and pelvic floor health.
 

In early January 2026, Boston Scientific Corporation announced that it had entered into a definitive agreement to acquire Valencia Therapeutics, Inc., a medical technology company focused on innovative treatments for bladder dysfunction.
 

Valencia is a neuromodulation company dedicated to improving the standard of care for bladder dysfunction. It designs and manufactures the eCoin® device for the treatment of urgency urinary incontinence (UUI) and completed a $35 million financing round in early 2025. The eCoin® System is an FDA-approved implantable tibial nerve stimulation (ITNS) device for the treatment of urgency urinary incontinence (UUI).
 

In October 2025, Boston Scientific signed an acquisition agreement to purchase the remaining equity of Nalu Medical for approximately $533 million in cash, with the transaction expected to close in the first half of 2026. Notably, Boston Scientific had strategically invested in Nalu as early as 2017, closely tracking its R&D and clinical progress over the years. Following this acquisition, Nalu will become part of Boston Scientific’s Neuromodulation division.
 

In April 2025, Boston Scientific acquired Bolt Medical for $600 million, officially entering the field of intravascular lithotripsy (IVL). It is reported that the IVL technology developed by Bolt Medical utilizes a laser platform to generate acoustic pressure waves within a balloon catheter, precisely fragmenting calcified plaques. Its visualized directional emitter ensures consistent energy delivery, making it suitable for the treatment of coronary and peripheral artery diseases.
 

In March 2025, Boston Scientific announced an agreement to acquire the remaining 90% equity stake in SoniVie for $360 million, completing its acquisition of the Israeli medical device company. SoniVie’s Alto System utilizes ultrasound-based renal denervation (RDN) technology to modulate renal sympathetic nerve activity through a minimally invasive approach. This acquisition will bring innovative renal denervation technology to Boston Scientific’s interventional cardiology portfolio.
 

In January 2025, Boston Scientific Corporation announced that it had entered into a definitive agreement to acquire Bolt Medical, Inc., to expand its cardiovascular portfolio. Bolt Medical specializes in the design and development of laser-based intravascular lithotripsy platforms for the treatment of coronary and peripheral artery disease.
 

　　……
 

Overall, Boston Scientific’s series of acquisitions—spanning urology, cardiovascular care, and chronic pain management—are essentially aimed at rapidly acquiring core technologies and products, addressing its own weaknesses, and building a technological moat. In the future, through this “strategic investment + acquisition” model, Boston Scientific’s product portfolio will continue to be refined, its business footprint will keep expanding, and its competitiveness in the medical technology sector will be further enhanced.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.